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with BO may assist in diagnosing PH. The treatment for PH
differs from BO and there is little understanding of their
interplay post-HSCT; further investigation is needed.291
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Background: Posterior reversible encephalopathy syndrome
(PRES) is a clinical syndrome characterized by vision
changes, alteredmental status, and seizures that are typically
caused by acute rise in blood pressure and resolve over time.
PRES has been reported after stem cell transplant (SCT) in
association with hypertension from calcineurin inhibitors
and steroids. The radiologic evaluation of PRES after SCT has
not been well described.
Design/Methods: A retrospective review of all cases of PRES
in SCT recipients from January of 2004 to December of 2013
was performed. PRES was diagnosed if the patient developed
encephalopathy, headache, seizures or visual disturbances
with a CT and/or MRI showing imaging ﬁndings compatible
with PRES.
Results: Twenty-two of 838 (2.6%) transplanted patients
were diagnosed with PRES, all of them allogeneic SCT re-
cipients. The majority (64%) were male with a median age of9.4 years (IQR 4.9-12.1) at time of SCT. Nine patients had a
marrow failure syndrome (41%), 7 of which had Fanconi
Anemia; 7 patients had an immune deﬁciency (32%); 5 had
an underlying malignancy (23%); and 1 patient had a meta-
bolic syndrome (4%). Twelve patients (55%) had a myeloa-
blative preparative regimen. All patients received
cyclosporine for graft versus host disease prophylaxis after
SCT and 11 (50%) were treated with additional immunosu-
pressants including steroids for GVHD at the time of event.
PRES was diagnosed at a median of 49 days (IQR 31-88) after
SCT. Nineteen patients (86%) presented with seizures, the
other 3 (14%) had altered mental status. All patients under-
went a brain CT and/or MRI, 21 of 22 patients (95%) received
a CT scan when they became symptomatic, which was
diagnostic of PRES in 8 of the 21 studies (38%). Eighteen
patients (82%) received MRI, 17 of the 18 (96%) were
consistent with PRES. The one MRI not consistent with PRES
was done 20 days after initial diagnosis, subsequent to res-
olution of the abnormal CT ﬁndings. Notably in 13 patients
initial CT scans did not demonstrate ﬁndings of PRES, which
were subsequently found on MRI. The median time elapsed
between CT and an MRI examination was 20 hours (range:
3.6 hours to 9 days). The overall survival in patients that
developed PRES was 35% (8 of 23 survived).
Conclusion: CT scan serves as a good diagnostic test in
emergency situations to rule out CNS bleed or infection in
SCT patients with acute mental status changes or seizures,
but it is not an adequate radiologic study for diagnosing of
PRES after SCT. Patients with clinical symptoms suggestive of
PRES, but negative CT, should undergo MRI of the brain after
the acute event is controlled to assist in diagnosis. MRI re-
sults diagnostic of PRES would prompt physicians to provide
good hypertension control and aid decision-making
regarding invasive diagnostic procedures (like lumbar
puncture) or intensiﬁcation of empiric antimicrobial therapy.292
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Background: The gut microbiome is an important immune
modulator, and previous work has shown important changes
in the gut microbiome associated with the occurrence of
GVHD. Studies in premature babies at risk for necrotizing
enterocolitis have shown that enteral human milk reduces
gut inﬂammation and bacterial translocation (Morrow et al,
2012).We hypothesized that enteral humanmilk given in the
peri-transplant period would be well tolerated and would
modify the microbiome and reduce inﬂammation.
Methods: In a pilot study, we treated 10 children<2 yrs with
donor enteral milk, and collected stool samples for micro-
biome analysis and blood samples for analysis of inﬂamma-
tory markers. Milk was obtained from the Mother’s Milk
Bank of the Northeast. Milk donors underwent standard
donor screening and milk was pasteurized before use. As
prebiotic and anti-inﬂammatory beneﬁts of are thought to
derive from human milk oligosaccharides produced by
fucosyltransferase2 (FUT2) and related gene biosynthesis
